Barrington Research restated their buy rating on shares of BioScrip (NASDAQ:BIOS) in a research report sent to investors on Friday morning, AnalystRatings.com reports. The firm currently has a $4.00 target price on the stock.
“We think they should have held one given that management is currently engaged in selling BIOS investors on the benefits of the pending Option Care transaction.”,” Barrington Research’s analyst wrote.
A number of other research analysts have also recently commented on the company. TheStreet cut BioScrip from a c- rating to a d rating in a research note on Wednesday, April 3rd. Canaccord Genuity dropped their price target on BioScrip from $5.00 to $3.50 and set a buy rating for the company in a research note on Monday, March 18th. Stephens cut BioScrip from an overweight rating to an equal weight rating and set a $2.51 price target for the company. in a research note on Monday, March 18th. BidaskClub upgraded BioScrip from a strong sell rating to a sell rating in a research note on Friday, March 15th. Finally, Zacks Investment Research cut BioScrip from a hold rating to a sell rating in a research note on Thursday, January 3rd. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and a consensus price target of $4.70.
BioScrip (NASDAQ:BIOS) last released its earnings results on Thursday, May 2nd. The company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.01. The business had revenue of $178.96 million for the quarter, compared to the consensus estimate of $179.23 million. During the same quarter in the previous year, the company earned ($0.12) earnings per share. The firm’s revenue for the quarter was up 6.2% on a year-over-year basis. On average, equities research analysts expect that BioScrip will post -0.25 earnings per share for the current year.
Several institutional investors and hedge funds have recently made changes to their positions in BIOS. Maven Securities LTD bought a new position in shares of BioScrip in the 4th quarter valued at $45,000. SG Americas Securities LLC acquired a new stake in BioScrip in the first quarter valued at $49,000. FNY Investment Advisers LLC increased its holdings in BioScrip by 840.9% in the first quarter. FNY Investment Advisers LLC now owns 25,000 shares of the company’s stock valued at $50,000 after purchasing an additional 22,343 shares during the period. Caxton Associates LP acquired a new stake in BioScrip in the fourth quarter valued at $52,000. Finally, BNP Paribas Arbitrage SA increased its holdings in BioScrip by 205.2% in the first quarter. BNP Paribas Arbitrage SA now owns 26,338 shares of the company’s stock valued at $53,000 after purchasing an additional 17,709 shares during the period. Institutional investors own 82.36% of the company’s stock.
BioScrip Company Profile
BioScrip, Inc provides infusion and home care management solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods.
Recommended Story: Price to Earnings Ratio (PE)
Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.